
Contact: | Investor Relations Inquiries |
Edmund E. Kroll, Jr. | |
Senior Vice President, Finance & Investor Relations | |
(212) 759-0382 | |
Media Inquiries | |
Marcela Manjarrez-Hawn | |
Senior Vice President and Chief Communications Officer | |
(314) 445-0790 | |
Total revenues (in millions) | $ | 14,181 | |
Health benefits ratio | 85.7 | % | |
SG&A expense ratio | 9.6 | % | |
GAAP diluted EPS | $ | 1.50 | |
Adjusted Diluted EPS (1) | $ | 1.80 | |
Total cash flow used in operations (in millions) | $ | (526 | ) |
(1) A full reconciliation of Adjusted Diluted EPS is shown on page six of this release. | |||
• | June 30, 2018 managed care membership of 12.8 million, an increase of 584,700 members, or 5%, over June 30, 2017. |
• | Total revenues for the second quarter of 2018 of $14.2 billion, representing 19% growth, compared to the second quarter of 2017. |
• | Health benefits ratio (HBR) of 85.7% for the second quarter of 2018, compared to 86.3% in the second quarter of 2017. |
• | Selling, general and administrative (SG&A) expense ratio and Adjusted SG&A expense ratio of 9.6% for the second quarter of 2018, compared to 9.3% for the second quarter of 2017. |
• | Diluted EPS for the second quarter of 2018 of $1.50, compared to $1.44 for the second quarter of 2017. |
• | Adjusted Diluted EPS for the second quarter of 2018 of $1.80, compared to $1.59 for the second quarter of 2017. |
• | Operating cash flow of $(526) million for the second quarter of 2018, and $1.3 billion for the six months ended June 30, 2018. As expected and highlighted at our June Investor Day, the second quarter cash flow was negatively affected by the repayment of $630 million of Medicaid expansion rate overpayments in California, which was previously accrued. |
• | In July 2018, we completed the acquisition of substantially all of the assets of Fidelis Care for $3.75 billion. The acquisition was funded through approximately $2.8 billion of new equity and approximately $1.8 billion of new long-term debt. Both offerings were completed in May 2018. |
• | In July 2018, our subsidiary, Health Net Federal Services, was awarded the next generation Military & Family Life Counseling Program contract. The awarded contract is up to ten years, including multiple one-year option periods. |
• | In July 2018, Centurion began operating under a contract to provide healthcare services for correctional facilities in Pima County, Arizona. In addition, Centurion's contracts for correctional facilities were reprocured in Florida, New Hampshire and Tennessee. |
• | In June 2018, our Kansas subsidiary, Sunflower Health Plan, was selected to continue providing managed care services to KanCare beneficiaries statewide. The new contract is expected to commence January 1, 2019. |
• | In June 2018, we announced our partnership with the National Council on Independent Living for the "Barrier Removal Fund" program. This program is an initiative to increase the accessibility of provider medical offices and services for people with disabilities. |
• | In May 2018, our Washington State subsidiary, Coordinated Care of Washington, was selected to provide expanded managed care services to Apple Health's Fully Integrated Managed Care (FIMC) Medicaid beneficiaries. This new contract integrates physical and behavioral health. |
• | In May 2018, our Iowa subsidiary, Iowa Total Care, Inc., was selected to negotiate a new statewide contract for the IA Health Link Program. Pending regulatory approval, the contract is expected to commence on July 1, 2019. |
• | In May 2018, our Florida subsidiary, Sunshine Health, was awarded a contract to provide physical and behavioral health care services in all 11 regions through Florida's Statewide Medicaid Managed Care Program, subject to regulatory approval and successful completion of readiness review. The five year contract is expected to begin December 1, 2018 and will be implemented by region through February 2019. |
• | In July 2018, FORTUNE magazine announced Centene's position of #210 in its annual ranking of the largest companies globally by revenue. |
• | In July 2018, Forbes announced Centene's position of #43 in its ranking of "Global 2000: Growth Champions." |
• | In June 2018, Centene and several of its subsidiaries earned Accreditation from NCQA, including SilverSummit Healthplan and Envolve Pharmacy Solutions. |
• | In May 2018, FORTUNE magazine announced Centene's position of #61 in its annual ranking of America's largest companies by revenue. |
• | In May 2018, at Decision Health's Ninth Annual Case in Point Platinum Awards, Centene and six of its subsidiaries were honored for their innovative programs. |
June 30 | |||||
2018 | 2017 | ||||
Medicaid: | |||||
TANF, CHIP & Foster Care | 5,852,000 | 5,854,400 | |||
ABD & LTSS | 874,200 | 843,500 | |||
Behavioral Health | 454,600 | 466,500 | |||
Total Medicaid | 7,180,800 | 7,164,400 | |||
Commercial | 2,051,700 | 1,743,600 | |||
Medicare (1) | 343,800 | 327,500 | |||
Correctional | 157,900 | 160,400 | |||
Total at-risk membership | 9,734,200 | 9,395,900 | |||
TRICARE eligibles | 2,851,500 | 2,823,200 | |||
Non-risk membership | 218,100 | — | |||
Total | 12,803,800 | 12,219,100 | |||
(1) Membership includes Medicare Advantage, Medicare Supplement, Special Needs Plans, and Medicare-Medicaid Plans (MMP). | |||||
June 30 | |||||
2018 | 2017 | ||||
Dual-eligible (2) | 489,500 | 467,500 | |||
Health Insurance Marketplace | 1,503,100 | 1,084,600 | |||
Medicaid Expansion | 1,079,700 | 1,101,900 | |||
(2) Membership includes dual-eligible ABD & LTSS and dual-eligible Medicare membership in the table above. | |||||
2018 | 2017 | % Change 2017-2018 | ||||||||
Medicaid | $ | 8,919 | $ | 8,068 | 11 | % | ||||
Commercial | 3,143 | 2,122 | 48 | % | ||||||
Medicare (1) | 1,203 | 1,134 | 6 | % | ||||||
Other | 916 | 630 | 45 | % | ||||||
Total Revenues | $ | 14,181 | $ | 11,954 | 19 | % | ||||
(1) Medicare includes Medicare Advantage, Medicare Supplement, Special Needs Plans, and MMP. | ||||||||||
• | For the second quarter of 2018, total revenues increased 19% to $14.2 billion, from $12.0 billion in the comparable period in 2017. The increase over prior year was due to growth in the Health Insurance Marketplace business in 2018, acquisitions, expansions and new programs in many of our states in 2017 and 2018, and the reinstatement of the health insurer fee in 2018. Total revenues also increased by approximately $500 million associated with pass through payments from the State of California received in the second quarter that were recorded in premium tax revenue and premium tax expense. These increases were partially offset by the impact of the removal of the in-home support services (IHSS) program from California's Medicaid contract in January 2018. |
• | Sequentially, total revenues increased 8% over the first quarter of 2018 primarily due to the pass through payments from the State of California noted above, the Illinois contract expansion and acquisitions. |
• | HBR of 85.7% for the second quarter of 2018 represents a decrease from 86.3% in the comparable period in 2017. The year-over-year decrease was primarily a result of membership growth in the Health Insurance Marketplace business and the reinstatement of the health insurer fee in 2018. These decreases were partially offset by the impact of retroactive minimum medical loss ratio (MLR) changes under California's Medicaid expansion program. |
• | HBR increased sequentially from 84.3% in the first quarter of 2018. The increase was primarily attributable to normal seasonality in the commercial business and the California minimum MLR changes noted above. These HBR increases were partially offset by the decrease in flu-related costs over the first quarter of 2018. |
• | The SG&A expense ratio and Adjusted SG&A expense ratio were 9.6% for the second quarter of 2018, compared to 9.3% for the second quarter of 2017. The year-over-year increase was primarily a result of growth in the Health Insurance Marketplace business, which operates at a higher SG&A expense ratio. |
Full Year 2018 | |||||||||
Low | High | ||||||||
Total revenues (in billions) | $ | 59.2 | $ | 60.0 | |||||
GAAP diluted EPS | $ | 4.25 | $ | 4.57 | |||||
Adjusted Diluted EPS (1) | $ | 6.80 | $ | 7.16 | |||||
HBR | 85.9 | % | 86.4 | % | |||||
SG&A expense ratio | 10.2 | % | 10.7 | % | |||||
Adjusted SG&A expense ratio (2) | 9.4 | % | 9.9 | % | |||||
Effective tax rate | 34.0 | % | 36.0 | % | |||||
Diluted shares outstanding (in millions) | 198.7 | 199.7 | |||||||
(1) | Adjusted Diluted EPS excludes amortization of acquired intangible assets of $0.81 to $0.83 per diluted share, acquisition related expenses of $1.62 to $1.64 per diluted share and California minimum MLR changes of $0.12 per diluted share. |
(2) | Adjusted SG&A expense ratio excludes acquisition related expenses of $422 million to $428 million, of which $400 million to $406 million will be incurred in the second half of 2018. |
Three Months Ended June 30, | Six Months Ended June 30, | ||||||||||||||
2018 | 2017 | 2018 | 2017 | ||||||||||||
GAAP net earnings | $ | 300 | $ | 254 | $ | 640 | $ | 393 | |||||||
Amortization of acquired intangible assets | 45 | 39 | 84 | 79 | |||||||||||
Acquisition related expenses | 1 | 1 | 22 | 6 | |||||||||||
California minimum medical loss ratio changes (1) | 30 | — | 30 | — | |||||||||||
Penn Treaty assessment expense (2) | — | — | — | 47 | |||||||||||
Income tax effects of adjustments (3) | (16 | ) | (14 | ) | (30 | ) | (48 | ) | |||||||
Adjusted net earnings | $ | 360 | $ | 280 | $ | 746 | $ | 477 | |||||||
(1) | The impact of retroactive minimum MLR changes under California’s Medicaid expansion program. |
(2) | Additional expense for the Company's estimated share of guaranty association assessment resulting from the liquidation of Penn Treaty for the six months ended June 30, 2017. |
(3) | The income tax effects of adjustments are based on the effective income tax rates applicable to adjusted (non-GAAP) results. |
Three Months Ended June 30, | Six Months Ended June 30, | Annual Guidance December 31, 2018 | |||||||||||||||
2018 | 2017 | 2018 | 2017 | ||||||||||||||
GAAP diluted EPS | $ | 1.50 | $ | 1.44 | $ | 3.39 | $ | 2.23 | $4.25 - $4.57 | ||||||||
Amortization of acquired intangible assets (1) | 0.17 | 0.14 | 0.35 | 0.28 | $0.81 - $0.83 | ||||||||||||
Acquisition related expenses (2) | 0.01 | 0.01 | 0.10 | 0.03 | $1.62 - $1.64 | ||||||||||||
California minimum medical loss ratio changes (3) | 0.12 | — | 0.12 | — | $0.12 | ||||||||||||
Penn Treaty assessment expense (4) | — | — | — | 0.17 | — | ||||||||||||
Adjusted Diluted EPS | $ | 1.80 | $ | 1.59 | $ | 3.96 | $ | 2.71 | $6.80 - $7.16 | ||||||||
(1) | The amortization of acquired intangible assets per diluted share presented above is net of an income tax benefit of $0.05 and $0.08 for the three months ended June 30, 2018 and 2017, respectively, and $0.10 and $0.17 for the six months ended June 30, 2018 and 2017, respectively; and an estimated $0.24 to $0.25 for the year ended December 31, 2018. |
(2) | The acquisition related expenses per diluted share presented above are net of an income tax benefit of $0.00 for both the three months ended June 30, 2018 and 2017, and $0.02 and $0.01 for the six months ended June 30, 2018 and 2017, respectively; and an estimated $0.50 to $0.51 for the year ended December 31, 2018. |
(3) | The impact of retroactive changes to the California minimum MLR is net of an income tax benefit of $0.03 and $0.04 for the three and six months ended June 30, 2018, respectively; and an estimated $0.03 to $0.04 for the year ended December 31, 2018. |
(4) | The Penn Treaty assessment expense per diluted share presented above is net of an income tax benefit of $0.09 for the six months ended June 30, 2017. |
Three Months Ended June 30, | Six Months Ended June 30, | Three Months Ended March 31, | |||||||||||||||||
2018 | 2017 | 2018 | 2017 | 2018 | |||||||||||||||
GAAP SG&A expenses | $ | 1,237 | $ | 1,065 | $ | 2,553 | $ | 2,156 | $ | 1,316 | |||||||||
Acquisition related expenses | 1 | 1 | 22 | 6 | 21 | ||||||||||||||
Penn Treaty assessment expense | — | — | — | 47 | — | ||||||||||||||
Adjusted SG&A expenses | $ | 1,236 | $ | 1,064 | $ | 2,531 | $ | 2,103 | $ | 1,295 | |||||||||
June 30, 2018 | December 31, 2017 | ||||||
(Unaudited) | |||||||
ASSETS | |||||||
Current assets: | |||||||
Cash and cash equivalents | $ | 6,707 | $ | 4,072 | |||
Premium and trade receivables | 4,067 | 3,413 | |||||
Short-term investments | 602 | 531 | |||||
Other current assets | 1,001 | 687 | |||||
Total current assets | 12,377 | 8,703 | |||||
Long-term investments | 5,746 | 5,312 | |||||
Restricted deposits | 1,943 | 135 | |||||
Property, software and equipment, net | 1,327 | 1,104 | |||||
Goodwill | 5,346 | 4,749 | |||||
Intangible assets, net | 1,501 | 1,398 | |||||
Other long-term assets | 503 | 454 | |||||
Total assets | $ | 28,743 | $ | 21,855 | |||
LIABILITIES, REDEEMABLE NONCONTROLLING INTERESTS AND STOCKHOLDERS’ EQUITY | |||||||
Current liabilities: | |||||||
Medical claims liability | $ | 5,003 | $ | 4,286 | |||
Accounts payable and accrued expenses | 3,803 | 4,165 | |||||
Return of premium payable | 529 | 549 | |||||
Unearned revenue | 523 | 328 | |||||
Current portion of long-term debt | 4 | 4 | |||||
Total current liabilities | 9,862 | 9,332 | |||||
Long-term debt | 6,275 | 4,695 | |||||
Other long-term liabilities | 1,898 | 952 | |||||
Total liabilities | 18,035 | 14,979 | |||||
Commitments and contingencies | |||||||
Redeemable noncontrolling interests | 11 | 12 | |||||
Stockholders’ equity: | |||||||
Preferred stock, $0.001 par value; authorized 10,000 shares; no shares issued or outstanding at June 30, 2018 and December 31, 2017 | — | — | |||||
Common stock, $0.001 par value; authorized 400,000 shares; 207,413 issued and 205,247 outstanding at June 30, 2018, and 180,379 issued and 173,437 outstanding at December 31, 2017 | — | — | |||||
Additional paid-in capital | 7,355 | 4,349 | |||||
Accumulated other comprehensive loss | (67 | ) | (3 | ) | |||
Retained earnings | 3,403 | 2,748 | |||||
Treasury stock, at cost (2,166 and 6,942 shares, respectively) | (81 | ) | (244 | ) | |||
Total Centene stockholders’ equity | 10,610 | 6,850 | |||||
Noncontrolling interest | 87 | 14 | |||||
Total stockholders’ equity | 10,697 | 6,864 | |||||
Total liabilities, redeemable noncontrolling interests and stockholders’ equity | $ | 28,743 | $ | 21,855 | |||
Three Months Ended June 30, | Six Months Ended June 30, | ||||||||||||||
2018 | 2017 | 2018 | 2017 | ||||||||||||
Revenues: | |||||||||||||||
Premium | $ | 12,113 | $ | 10,905 | $ | 24,016 | $ | 21,543 | |||||||
Service | 762 | 536 | 1,415 | 1,063 | |||||||||||
Premium and service revenues | 12,875 | 11,441 | 25,431 | 22,606 | |||||||||||
Premium tax and health insurer fee | 1,306 | 513 | 1,944 | 1,072 | |||||||||||
Total revenues | 14,181 | 11,954 | 27,375 | 23,678 | |||||||||||
Expenses: | |||||||||||||||
Medical costs | 10,380 | 9,413 | 20,419 | 18,735 | |||||||||||
Cost of services | 658 | 456 | 1,201 | 897 | |||||||||||
Selling, general and administrative expenses | 1,237 | 1,065 | 2,553 | 2,156 | |||||||||||
Amortization of acquired intangible assets | 45 | 39 | 84 | 79 | |||||||||||
Premium tax expense | 1,189 | 543 | 1,735 | 1,133 | |||||||||||
Health insurer fee expense | 183 | — | 354 | — | |||||||||||
Total operating expenses | 13,692 | 11,516 | 26,346 | 23,000 | |||||||||||
Earnings from operations | 489 | 438 | 1,029 | 678 | |||||||||||
Other income (expense): | |||||||||||||||
Investment and other income | 65 | 45 | 106 | 86 | |||||||||||
Interest expense | (80 | ) | (62 | ) | (148 | ) | (124 | ) | |||||||
Earnings from operations, before income tax expense | 474 | 421 | 987 | 640 | |||||||||||
Income tax expense | 175 | 169 | 350 | 256 | |||||||||||
Net earnings | 299 | 252 | 637 | 384 | |||||||||||
Loss attributable to noncontrolling interests | 1 | 2 | 3 | 9 | |||||||||||
Net earnings attributable to Centene Corporation | $ | 300 | $ | 254 | $ | 640 | $ | 393 | |||||||
Net earnings per common share attributable to Centene Corporation: | |||||||||||||||
Basic earnings per common share | $ | 1.53 | $ | 1.47 | $ | 3.46 | $ | 2.28 | |||||||
Diluted earnings per common share | $ | 1.50 | $ | 1.44 | $ | 3.39 | $ | 2.23 | |||||||
Six Months Ended June 30, | |||||||
2018 | 2017 | ||||||
Cash flows from operating activities: | |||||||
Net earnings | $ | 637 | $ | 384 | |||
Adjustments to reconcile net earnings to net cash provided by operating activities | |||||||
Depreciation and amortization | 215 | 173 | |||||
Stock compensation expense | 67 | 62 | |||||
Deferred income taxes | 4 | (58 | ) | ||||
Changes in assets and liabilities | |||||||
Premium and trade receivables | (553 | ) | (696 | ) | |||
Other assets | 2 | 65 | |||||
Medical claims liabilities | 717 | 243 | |||||
Unearned revenue | 202 | 241 | |||||
Accounts payable and accrued expenses | (865 | ) | (257 | ) | |||
Other long-term liabilities | 865 | 781 | |||||
Other operating activities, net | 29 | 4 | |||||
Net cash provided by operating activities | 1,320 | 942 | |||||
Cash flows from investing activities: | |||||||
Capital expenditures | (362 | ) | (181 | ) | |||
Purchases of investments | (1,375 | ) | (1,317 | ) | |||
Sales and maturities of investments | 721 | 1,015 | |||||
Acquisitions, net of cash acquired | (237 | ) | — | ||||
Other investing activities, net | — | (1 | ) | ||||
Net cash used in investing activities | (1,253 | ) | (484 | ) | |||
Cash flows from financing activities: | |||||||
Proceeds from the issuance of common stock | 2,780 | — | |||||
Proceeds from long-term debt | 5,146 | 810 | |||||
Payments of long-term debt | (3,471 | ) | (762 | ) | |||
Common stock repurchases | (13 | ) | (15 | ) | |||
Purchase of noncontrolling interest | (63 | ) | — | ||||
Other financing activities, net | (1 | ) | 6 | ||||
Net cash provided by financing activities | 4,378 | 39 | |||||
Net increase in cash, cash equivalents and restricted cash | 4,445 | 497 | |||||
Cash, cash equivalents, and restricted cash and cash equivalents, beginning of period | 4,089 | 3,936 | |||||
Cash, cash equivalents, and restricted cash and cash equivalents, end of period | $ | 8,534 | $ | 4,433 | |||
Supplemental disclosures of cash flow information: | |||||||
Interest paid | $ | 130 | $ | 99 | |||
Income taxes paid | $ | 195 | $ | 205 | |||
Equity issued in connection with acquisitions | $ | 507 | $ | — | |||
Q2 | Q1 | Q4 | Q3 | Q2 | |||||||||||||||
2018 | 2018 | 2017 | 2017 | 2017 | |||||||||||||||
MANAGED CARE MEMBERSHIP BY LINE OF BUSINESS | |||||||||||||||||||
Medicaid: | |||||||||||||||||||
TANF, CHIP & Foster Care | 5,852,000 | 5,776,600 | 5,807,300 | 5,809,400 | 5,854,400 | ||||||||||||||
ABD & LTSS | 874,200 | 866,000 | 846,200 | 850,300 | 843,500 | ||||||||||||||
Behavioral Health | 454,600 | 454,500 | 463,700 | 467,400 | 466,500 | ||||||||||||||
Total Medicaid | 7,180,800 | 7,097,100 | 7,117,200 | 7,127,100 | 7,164,400 | ||||||||||||||
Commercial | 2,051,700 | 2,161,200 | 1,558,300 | 1,657,800 | 1,743,600 | ||||||||||||||
Medicare (1) | 343,800 | 343,400 | 333,700 | 331,000 | 327,500 | ||||||||||||||
Correctional | 157,900 | 157,300 | 157,500 | 158,000 | 160,400 | ||||||||||||||
Total at-risk membership | 9,734,200 | 9,759,000 | 9,166,700 | 9,273,900 | 9,395,900 | ||||||||||||||
TRICARE eligibles | 2,851,500 | 2,851,500 | 2,824,100 | 2,823,200 | 2,823,200 | ||||||||||||||
Non-risk membership | 218,100 | 218,900 | 216,300 | 213,900 | — | ||||||||||||||
Total | 12,803,800 | 12,829,400 | 12,207,100 | 12,311,000 | 12,219,100 | ||||||||||||||
(1) Membership includes Medicare Advantage, Medicare Supplement, Special Needs Plans, and MMP. | |||||||||||||||||||
NUMBER OF EMPLOYEES | 41,200 | 34,800 | 33,700 | 32,400 | 31,500 | ||||||||||||||
DAYS IN CLAIMS PAYABLE (2) | 44 | 43 | 41 | 42 | 40 | ||||||||||||||
(2) Days in claims payable is a calculation of medical claims liabilities at the end of the period divided by average claims expense per calendar day for such period. | |||||||||||||||||||
CASH, INVESTMENTS AND RESTRICTED DEPOSITS (in millions) | |||||||||||||||||||
Regulated | $ | 11,455 | $ | 11,398 | $ | 9,740 | $ | 9,633 | $ | 9,673 | |||||||||
Unregulated | 3,543 | 452 | 310 | 308 | 291 | ||||||||||||||
Total | $ | 14,998 | $ | 11,850 | $ | 10,050 | $ | 9,941 | $ | 9,964 | |||||||||
DEBT TO CAPITALIZATION | 37.0 | % | 40.6 | % | 40.6 | % | 41.5 | % | 42.5 | % | |||||||||
DEBT TO CAPITALIZATION EXCLUDING NON-RECOURSE DEBT (3) | 36.7 | % | 40.3 | % | 40.3 | % | 41.2 | % | 42.1 | % | |||||||||
(3) The non-recourse debt represents the Company's mortgage note payable ($59 million at June 30, 2018) and construction loan payable ($26 million at June 30, 2018). | |||||||||||||||||||
Debt to capitalization is calculated as follows: total debt divided by (total debt + total equity). | |||||||||||||||||||
Three Months Ended June 30, | Six Months Ended June 30, | ||||||||||
2018 | 2017 | 2018 | 2017 | ||||||||
HBR | 85.7 | % | 86.3 | % | 85.0 | % | 87.0 | % | |||
SG&A expense ratio | 9.6 | % | 9.3 | % | 10.0 | % | 9.5 | % | |||
Adjusted SG&A expense ratio | 9.6 | % | 9.3 | % | 10.0 | % | 9.3 | % | |||
Balance, June 30, 2017 | $ | 4,170 | ||
Reinsurance recoverable | 10 | |||
Balance, June 30, 2017, net | 4,160 | |||
Incurred related to: | ||||
Current period | 39,894 | |||
Prior period | (359 | ) | ||
Total incurred | 39,535 | |||
Paid related to: | ||||
Current period | 35,184 | |||
Prior period | 3,525 | |||
Total paid | 38,709 | |||
Balance, June 30, 2018, net | 4,986 | |||
Plus: Reinsurance recoverable | 17 | |||
Balance, June 30, 2018 | $ | 5,003 | ||